(227 days)
No
The description focuses on automated pipetting and sample preparation using preprogrammed protocols, with no mention of AI or ML capabilities.
No
The device is described as preparing samples for flow cytometric analysis, which is a diagnostic purpose, not a therapeutic one. It processes blood samples for in vitro diagnostic use and does not mention treating or preventing any disease or condition.
Yes
The device is intended "to prepare human whole blood for flow cytometric analysis on BD FACSCanto II flow cytometry systems" using "previously cleared assays for flow cytometric analysis," and the text explicitly states "For in vitro diagnostic use." This indicates that the device is part of a system used to process samples for diagnostic testing.
No
The device description explicitly states it combines fluidic, optic, robotic, and electronic components, including a robotic pipetting module, power supply, central controller unit, fluid pumps, and a barcode reader. These are all hardware components, making it a hardware device with integrated software, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "For in vitro diagnostic use."
- Intended Use: The device is intended to prepare human whole blood for flow cytometric analysis using previously cleared IVD assays. This preparation is a crucial step in an in vitro diagnostic process.
- Device Description: The description details a system that handles and processes biological samples (whole blood) and reagents for analysis, which is characteristic of IVD devices.
- Performance Studies: The performance studies (Accuracy, Precision, Carryover) are conducted according to CLSI guidelines, which are standard for evaluating the performance of clinical laboratory devices, including IVDs.
- Predicate Device: The predicate device listed is also a "Sample Prep Assistant," implying a history of similar devices being used in a diagnostic context.
Therefore, based on the provided information, the BD FACSTM Sample Prep Assistant III is an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The BD FACSTM Sample Prep Assistant III is intended to prepare human whole blood for flow cytometric analysis on BD FACSCanto II flow cytometry systems.
Pipetting blood, reagents and lysing solution using the following previously cleared assays for flow cytometric analysis on BD FACSCanto II flow cytometry systems:
- . BD Multitest 6-Color TBNK Reagent with or without BD Trucount Tubes
- BD Multitest IMK Kit with or without BD Trucount Tubes .
- BD Multitest CD3 FITC/CD16+CD56 PE/CD45 PerCP/CD19 APC with or . without BD Trucount Tubes
- BD Multitest CD3 FITC/CD8 PE/CD45 PerCP/CD4 APC with or without BD . Trucount Tubes
For in vitro diagnostic use.
Product codes
GKZ
Device Description
The BD FACS Sample Prep Assistant III is a microprocessor-controlled pipetting and diluting system which automatically prepares whole blood samples using the lyse / nowash sample preparation method for flow cytometry. Used as an accessory to the BD FACSCanto flow cytometer, the SPA III combines fluidic, optic, robotic, and electronic components to automatically prepare samples for acquisition and analysis.
The SPA III pierces the sample tube cap to withdraw sample, aliquots blood and reagent into daughter tubes, and mixes the sample according to preprogrammed or custom protocols. The device also adds lysing solution and automates cleaning procedures. The unit consists of an enclosure, one robotic pipetting module moving in the X/Y/Z axes, a power supply, a central controller unit, fluid pumps, and a barcode reader.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
| Study | Study Design | Results |
|---|---|---|
| Accuracy | Based on Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, CLSI document EP9-A2. | The SPA III with the BD FACSCanto system demonstrated equivalent performance. |
| Precision | Based on Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline, CLSI document EP5-A2. | The SPA III with the BD FACSCanto system demonstrated system precision within specification. |
| Carryover | Based on recommendations contained in Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA, December 4, 2001. | The SPA III with the BD FACSCanto system demonstrated system carryover within specification. |
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.5220 Automated differential cell counter.
(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”
0
510(k) SUMMARY
MAR - 7 2011
This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of Safe Medical Devices Act of 1990 and 21 CFR 807.92.
The assigned 510(k) number is K102064.
Submitter Information (21 CFR 807.92(a)(1))
Submitter: BD Biosciences 2350 Qume Drive San Jose, CA 95131 USA
Contact: Marc Glazer Manager, US Regulatory Affairs (408) 954-2355 (408) 954-2495 (FAX)
Summary Date: February 25, 2011
Device Name / Classification (21 CFR 807.92(a)(2))
Name: BD FACSTM Sample Prep Assistant III accessory to the BD FACSCanto™ system with BD FACSCanto™ clinical software Class II (21 CFR 864.5220) – Automated Differential Cell Counter Classification:
Substantially Equivalent/Predicate Device (21 CFR 807.92(a)(3))
The BD FACS Sample Prep Assistant III (SPA III) is substantially equivalent to the BD FACS™ Sample Prep Assistant II (SPA II), both of which are used with the BD FACSCanto system with BD FACSCanto Clinical Software. The SPA III and SPA II are used for the same assay preparation, and result in equivalent performance characteristics.
1
Device Description (21 CFR 807.92(a)(4))
The BD FACS Sample Prep Assistant III is a microprocessor-controlled pipetting and diluting system which automatically prepares whole blood samples using the lyse / nowash sample preparation method for flow cytometry. Used as an accessory to the BD FACSCanto flow cytometer, the SPA III combines fluidic, optic, robotic, and electronic components to automatically prepare samples for acquisition and analysis.
The SPA III pierces the sample tube cap to withdraw sample, aliquots blood and reagent into daughter tubes, and mixes the sample according to preprogrammed or custom protocols. The device also adds lysing solution and automates cleaning procedures. The unit consists of an enclosure, one robotic pipetting module moving in the X/Y/Z axes, a power supply, a central controller unit, fluid pumps, and a barcode reader.
Intended Use (21 CFR 807.92(a)(5))
The BD FACSTM Sample Prep Assistant III is intended to prepare human whole blood for flow cytometric analysis on BD FACSCanto II flow cytometry systems.
Indications for Use
Pipetting blood, reagents and lysing solution using the following previously cleared assays for flow cytometric analysis on BD FACSCanto II flow cytometry systems:
- . BD Multitest 6-Color TBNK Reagent with or without BD Trucount Tubes
- BD Multitest IMK Kit with or without BD Trucount Tubes .
- BD Multitest CD3 FITC/CD16+CD56 PE/CD45 PerCP/CD19 APC with or . without BD Trucount Tubes
- BD Multitest CD3 FITC/CD8 PE/CD45 PerCP/CD4 APC with or without BD . Trucount Tubes
For in vitro diagnostic use.
2
Technological Characteristics (21 CFR 807.92(a)(6))
The following summary table describes the similarities and differences between the SPA II and SPA III when used with the BD FACSCanto system with BD FACSCanto clinical software.
| Characteristic | BD FACS Sample Prep
Assistant II | BD FACS Sample Prep
Assistant III |
|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (predicate) | (modification) |
| Intended Use | When used as a pre-analytical
component of the BD
FACSCanto system, the SPA II
becomes an accessory to the BD
FACSCanto system but does not
change the BD FACSCanto
system's intended use. | The BD FACS™ Sample Prep
Assistant III is intended to
prepare human whole
blood for flow cytometric
analysis on BD FACSCanto II
flow cytometry systems. |
| Sample Type | Whole blood | Same |
| Device
Classification and
Product Code as
a Stand-alone
Device | Automated Differential Cell
Counter
21 CFR 864.5220
Product Code: GKZ
Class II | Same |
| Preparation
Method | Automated | Same |
| Pipetting Syringe | 500 µL sample/reagent syringe
2.5 mL lyse syringe | 1 mL sample/reagent syringe
10 mL lyse syringe |
| Supported
primary blood
sample tubes | Vacutainer | Vacutainer
Sarstedt |
| Probe rinse | One 30 second wash | 3 pulses of approximately 1
second |
| Single-dispense
excess drawn
reagent (waste) | 5 µL | 4 µL |
Table 1: Similarities and Differences
3
The SPA III has modifications over the previous generation. These include reduced sample processing time through the use of larger syringes and reduced wash time; reduced reagent waste; and software upgrades to provide usability enhancements.
| Study | Study Design | Results |
|---|---|---|
| Accuracy | Based on Method Comparison and | |
| Bias Estimation Using Patient | ||
| Samples; Approved Guideline, CLSI | ||
| document EP9-A2. | The SPA III with the BD | |
| FACSCanto system demonstrated | ||
| equivalent performance. | ||
| Precision | Based on Evaluation of Precision | |
| Performance of Clinical Chemistry | ||
| Devices; Approved Guideline, CLSI | ||
| document EP5-A2. | The SPA III with the BD | |
| FACSCanto system demonstrated | ||
| system precision within | ||
| specification. | ||
| Carryover | Based on recommendations | |
| contained in Class II Special | ||
| Controls Guidance Document: | ||
| Premarket Notifications for | ||
| Automated Differential Cell | ||
| Counters for Immature or Abnormal | ||
| Blood Cells; Final Guidance for | ||
| Industry and FDA, | ||
| December 4, 2001. | The SPA III with the BD | |
| FACSCanto system demonstrated | ||
| system carryover within | ||
| specification. |
Table 2: Performance Data (21 CFR 807.92(b)(1)and (2))
Conclusions from Performance Data (21 CFR 807.92(b)(3))
The BD FACS Sample Prep Assistant III with the BD FACSCanto system with BD FACSCanto clinical software demonstrates substantial equivalence to the predicate method.
4
Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three stripes forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
BD Biosciences c/o Marc Glazer, Ph.D. Manager, US Regulatory Affairs 2350 Qume Drive San Jose, CA 95131 USA
MAR 0 7 2011
Re: K102064
Trade/Device Name: BD FACSTM Sample Prep Assistant III Regulation Number: 21 CFR 864.5220 Regulation Name: Automated differential cell counter Regulatory Class: Class II Product Code: GKZ Dated: February 17, 2011 ( Received: February 18, 2011
Dear Dr. Glazer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice
5
Page 2 - Marc Glazer, Ph.D.
requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Maria Mchon
Maria M. Chan, Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Indications for Use Statement
510(k) Number (if known): K102064
Device Name: BD FACSTM Sample Prep Assistant III
Indications for Use:
Pipetting blood, reagents and lysing solution using the following previously cleared assays for flow cytometric analysis on BD FACSCanto II flow cytometry systems:
- . BD Multitest 6-Color TBNK Reagent with or without BD Trucount Tubes
- . BD Multitest IMK Kit with or without BD Trucount Tubes
- BD Multitest CD3 FITC/CD16+CD56 PE/CD45 PerCP/CD19 APC with or . without BD Trucount Tubes
- BD Multitest CD3 FITC/CD8 PE/CD45 PerCP/CD4 APC with or without BD . Trucount Tubes
For in vitro diagnostic use.
Prescription Use X (Part.21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division Sign-Off
fice of in Vitro Dlagnostic Device Evaluation and Safety
510(k) K102064